These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 20407454)

  • 1. Precompetitive research: a new prescription for drug development?
    Woodcock J
    Clin Pharmacol Ther; 2010 May; 87(5):521-3. PubMed ID: 20407454
    [No Abstract]   [Full Text] [Related]  

  • 2. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 3. Precompetitive activity to address the biological data needs of drug discovery.
    Sidders B; Brockel C; Gutteridge A; Harland L; Jansen PG; McEwen R; Michalovich D; Seidel H; Weiss B; Williams-Jones B; Woodwark M
    Nat Rev Drug Discov; 2014 Feb; 13(2):83-4. PubMed ID: 24481293
    [No Abstract]   [Full Text] [Related]  

  • 4. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Europe fiddles while innovation burns.
    Frantz S
    Nat Rev Drug Discov; 2005 Sep; 4(9):704-5. PubMed ID: 16178115
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 7. Aligning pharmaceutical innovation with medical need.
    Nathan C
    Nat Med; 2007 Mar; 13(3):304-8. PubMed ID: 17342145
    [No Abstract]   [Full Text] [Related]  

  • 8. What's fueling the biotech engine?
    Aggarwal S
    Nat Biotechnol; 2007 Oct; 25(10):1097-104. PubMed ID: 17921989
    [No Abstract]   [Full Text] [Related]  

  • 9. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
    Micklus A; Muntner S
    Nat Rev Drug Discov; 2015 Feb; 14(2):84-5. PubMed ID: 25633786
    [No Abstract]   [Full Text] [Related]  

  • 10. Arguments against precompetitive collaboration.
    Vargas G; Boutouyrie B; Ostrowitzki S; Santarelli L
    Clin Pharmacol Ther; 2010 May; 87(5):527-9. PubMed ID: 20407456
    [No Abstract]   [Full Text] [Related]  

  • 11. Open-minded to open innovation and precompetitive collaboration.
    Wagner JA
    Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug Regulation and Pricing--Can Regulators Influence Affordability?
    Eichler HG; Hurts H; Broich K; Rasi G
    N Engl J Med; 2016 May; 374(19):1807-9. PubMed ID: 27168431
    [No Abstract]   [Full Text] [Related]  

  • 13. Precompetitive consortia in biomedicine--how are we doing?
    Mittleman B; Neil G; Cutcher-Gershenfeld J
    Nat Biotechnol; 2013 Nov; 31(11):979-85. PubMed ID: 24213770
    [No Abstract]   [Full Text] [Related]  

  • 14. What's fueling the biotech engine-2007.
    Aggarwal S
    Nat Biotechnol; 2008 Nov; 26(11):1227-33. PubMed ID: 18997759
    [No Abstract]   [Full Text] [Related]  

  • 15. A bitter pill.
    Nat Chem; 2010 May; 2(5):337. PubMed ID: 20414223
    [No Abstract]   [Full Text] [Related]  

  • 16. David Haslam. Interview by Asher Mullard.
    Haslam D
    Nat Rev Drug Discov; 2013 Jul; 12(7):500. PubMed ID: 23764976
    [No Abstract]   [Full Text] [Related]  

  • 17. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
    Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
    Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jumpstarting research into neglected diseases.
    Leslie M
    Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.